Table 2.
Postoperative characteristics of the study cohort stratified by biochemical and clinical outcome
| Characteristicsa | Stratified by Biochemical Outcome | Stratified by Clinical Outcome | ||||
|---|---|---|---|---|---|---|
| Complete (n = 26) | Partial (n = 2) | Absent (n = 5) | Complete (n = 7) | Partial (n = 24) | Absent (n = 5) | |
| Pathology, no. (%) [n = 33; n = 36] | ||||||
| Adenoma | 20 (77) | 2 (100) | 3 (60) | 7 (100) | 19 (79) | 2 (40) |
| Hyperplasia | 6 (23) | 0 (0) | 2 (40) | 0 (0) | 5 (21) | 3 (60) |
| SBP (postoperative), mean (SD), mm Hg [n = 32; n = 36] | 133 (11) | 143 (5) | 130 (8) | 125 (10) | 134 (11) | 140 (10) |
| Reduction in SBPb, mean (SD), mm Hg [n = 32; n = 36] | 17 (21) | -4 (18) | 17 (12) | 24 (22) | 17 (17) | 0 (13) |
| Reduction in SBPb, mean (SD), % [n = 32; n = 36] | 10.1 (13.2) | -3.1 (13) | 10.9 (7.2) | 14.6 (14.7) | 10.4 (11.3) | -0.5 (11.0) |
| DBP (postoperative), mean (SD), mm Hg [n = 32; n = 36] | 84 (7) | 80 (0) | 82 (7) | 82 (3) | 84 (8) | 87 (8) |
| Reduction in DBPb, mean (SD), mm Hg [n = 32; n = 36] | 9 (12) | 1 (7) | 7 (5) | 12 (16) | 8 (10) | -1 (5) |
| Reduction in DBPb, mean (SD), % [n = 32; n = 36] | 7.9 (13.5) | 0.9 (8.7) | 7.7 (6.0) | 11 (16.9) | 7.8 (10.8) | -1.3 (6.1) |
| Medications (postoperative), median (IQR), DDD [n = 32; n = 36] | 1 (2.9) | ND | 3.3 (3.3) | 0 (0) | 2.2 (3) | 1.5 (2.4) |
| Reduction in medicationsb, median (IQR), DDD [n = 32; n = 36] | 2.3 (2.7) | ND | 1.7 (4.7) | 4.0 (4.5) | 2.2 (2) | 0 (2) |
| Reduction in medicationsb, median (IQR), % [n = 32; n = 36] | 71.4 (62.8) | ND | 33.3 (77.9) | 100 (0) | 56.8 (41.4) | 0 (79.2) |
| PAC (postoperative), median (IQR), pmol/L [n = 32; n = 33] | 164 (167) | ND | 470 (668) | 204 (166) | 165 (177) | 395 (736) |
| ARR (postoperative), median (IQR), % ULN [n = 32; n = 33] | 25 (26) | ND | 488 (354) | 20 (41) | 30 (74) | 54 (536) |
| Serum potassium (postoperative), mean (SD), mmol/L [n = 32; n = 34] | 4.6 (0.6) | 4.2 (0.3) | 4.2 (0.5) | 4.5 (0.4) | 4.6 (0.6) | 4.0 (0.5) |
| Serum creatinine (postoperative), mean (SD), µmol/L [n = 30; n = 31] | 111.4 (24.9) | 88.5 (14.8) | 101.3 (35.1) | 105.2 (20.3) | 111.7 (27.6) | 80.7 (7.5) |
| eGFR (postoperative), mean (SD), mL/min/1.73 m2 [n = 30; n = 31] | 61.2 (14.4) | 79.3 (19.0) | 63.4 (16.1) | 63.0 (13.5) | 60.7 (14.7) | 84.9 (6.2) |
| Reduction in eGFRb, mean (SD), mL/min/1.73 m2 [n = 28; n = 29] | 17.7 (18.3) | ND | -2.7 (0.4) | 15.3 (17.5) | 17.0 (19.4) | 24.2 (25.8) |
| Follow-up time, median (IQR), months [n = 33; n = 36] | 2.2 (3.9) | ND | 9.0 (26.0) | 3.1 (6.1) | 22.6 (56.2) | 2.5 (23.8) |
Number of patients with missing data (no.; % of clinical outcomes group) included: PAC (4; 11%), ARR (4; 11%), potassium (2; 6%), creatinine (5; 14%), and eGFR (5; 14%). Number of patients with missing data (no.; % of biochemical outcomes group) included: SBP, DBP, and medications (1; 3%), potassium (1; 3%), creatinine (3; 9%), and eGFR (3; 9%).
Abbreviations: ARR, aldosterone-to-renin ratio; DBP, diastolic blood pressure; DDD, defined daily dose; eGFR, estimated glomerular filtration rate; IQR, interquartile range; ND, no data; PAC, plasma aldosterone concentration; SBP, systolic blood pressure; SD, standard deviation; ULN, upper limit of normal.
an shown for biochemical and clinical outcomes, respectively.
b Change is postoperative value subtracted from preoperative value; a negative change indicates an increase in value.